Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study

Psychiatric Clinics of North America

Volumn 26, Issue 2, 2003, Pages 457-494

  Fava, Maurizio ^a   Rush, A John ^b   Trivedi, Madhukar H ^b   Nierenberg, Andrew A ^a   Thase, Michael E ^c,d   Sackeim, Harold A ^g,h   Quitkin, Frederic M ^g,h   Wisniewski, Steven ^c   Lavori, Philip W ^e,f   Rosenbaum, Jerrold F ^a   Kupfer, David J ^c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g Columbia Univ Coll of Phys/Surg ^*  (United States)

^h NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; FLUOXETINE; GABAPENTIN; IMIDAZOPYRIDINE DERIVATIVE; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROXINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DISEASE COURSE; DRUG CHOICE; DRUG COST; DRUG RESISTANCE; DRUG RESPONSE; DRUG SAFETY; HUMAN; INSOMNIA; MAJOR DEPRESSION; PREDICTION; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037986382     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(02)00107-7     Document Type: Review

References (159)

1. Frank E, Karp JF, Rush AJ. Efficacy of treatments for major depression. Psychopharmacol Bull 1993;29:457-75.
2. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200.
3. Agosti V. Predictors of persistent social impairment among recovered depressed outpatients. J Affect Disord 1999;55:215-9.
4. Weissman MM, Bruce ML, Leaf PJ, et al. Affective disorders. In: Robins LN, Regier DA, editors. Psychiatric disorders in America: the Epidemiologic Catchment Area Study. New York: The Free Press; 1991. p. 53.
5. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSMIII-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
6. Depression Guideline Panel. Clinical practice guideline. Number 5. Depression in primary care, vol. 1. Detection and diagnosis. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93-0550; 1993.
7. Mueller TI, Leon AC. Recovery, chronicity, and levels of psychopathology in major depression. Psychiatr Clin North Am 1996;19:85-102.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Association; 1994.
9. Keller MB, Klein DN, Hirschfeld RMA, et al. Results of the DSM-IV Mood Disorders Field Trial. Am J Psychiatry 1995;152:843-9.
10. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998;55:694-700.
11. Thase ME, Howland RH. Refractory depression: relevance of psychosocial factors and therapies. Psychiatr Ann 1994;24:232-40.
12. Depression Guideline Panel. Clinical practice guideline. Number 5. Depression in primary care, vol. 2. Treatment of major depression. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93-0551; 1993.
13. Wells KB, Stewart A, Hayes RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989;262:914-9.
14. Murray CJ, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science 1996;274:740-3.
15. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-18.
16. Simon GE, Von Korff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry 1998;52:850-6.
17. Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry 1997;54:989-91.
18. Judd LL, Paulus MP, Wells KB. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry 1996;153:1411-6.
19. Miller IW, Keitner GI, Schatzberg AJ, et al. The treatment of chronic depression, Part 3: Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608-19.
20. Rush AJ, Trivedi MH. Treating depression to remission. Psychiatr Ann 1995;25:704-5.
21. McCombs JS, Nichol MB. Pharmacy-enforced outpatient drug treatment protocols: a case study of Medical restrictions for cefaclor. Ann Pharmacother 1993;27:155-61.
22. Jarrett RB, Rush AJ. Short-term psychotherapy of depressive disorders: current status and future directions. Psychiatry: Interpers Biol Process 1994;57:115-32.
23. Frank E, Prien R, Jarrett RB, Keller MB, et al. Conceptualization and rationale for consensus definitions of response, remission, recovery, relapse and recurrence in major depressive disorder. Arch Gen Psychiatry 1991;48:851-5.
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
25. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
26. Riso LP, Thase ME, Howland RH, et al. A prospective test of criteria for response, remission, relapse, recovery, and recurrence in patients treated with cognitive behavior therapy. J Affect Disord 1997;43:131-42.
27. Rush AJ, Thase ME. Psychotherapies for depressive disorders. In: Maj M, Sartorius N, editors. WPA Series. Evidence and experience in psychiatry, vol. 1. Depressive disorders. Chichester, United Kingdom: John Wiley & Sons; 1999, p, 161.
28. Akiskal HS. Subaffective disorders: dysthymic, cyclothymic, and bipolar II disorders in the "borderline" realm. Psychiatr Clin North Am 1981;4:25-46.
29. Howland RH. General health, health care utilization, and medical comorbidity in dysthymia. Int J Psychiatr Med 1993;23:211-38.
30. American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993;150(suppl 4):1-26.
31. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157(suppl 4):1-45.
32. Crismon ML, Trivedi MH, Pigott TA, et al. The Texas Medication Algorithm Project. Report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder. J Clin Psychiatry 1999;60:142-56.
33. Gilbert DA, Altshuler KZ, Rago WV, et al. Texas Medication Algorithm Project: definitions, rationale and methods to develop medication algorithms. J Clin Psychiatry 1998;59:345-51.
34. Rush AJ, Carmody T, Reimitz PE. The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatric Res 2000;9:49-59.
35. Rush AJ, Prien RF. From scientific knowledge to the clinical practice of psychopharmacology: Can the gap be bridged? Psychopharmacol Bull 1995;31:7-20.
36. Fava M, Kaji J. Continuation and maintenance treatments of major depressive disorder. Psychiatr Ann 1994;24:281-90.
37. Keller MB, Gelenberg AJ, Hirschfeld RMA, et al. The treatment of chronic depression, Part 2: A double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998;59:598-607.
38. Fava M, Kaji J, Davidson K. Pharmacological strategies for treatment-resistant major depression. In: Pollack MH, Otto MW, Rosenbaum JF, editors. Challenges in clinical practice: pharmacological and psychosocial strategies. New York: Guilford Press; 1996. p. 3.
39. Rosenbaum JF, Fava M, Nierenberg AA, Sachs G. Treatment-resistant mood disorders. In: Gabbard GO, editor. Treatments of psychiatric disorders, vol. 2. 3rd edition. Washington, DC: American Psychiatric Press; 2001. p. 1307.
40. Byrne S, Rothschild AJ. Psychiatrists' responses to failure of maintenance therapy with antidepressants. Psychiatr Serv 1997;48:835-7.
41. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-9.
42. Frank E, Perel JM, Mallinger AG, et al. Relationship of pharmacologic compliance to long-term prophylaxis in recurrent depression. Psychopharmacol Bull 1992;28:231-5.
43. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomized comparison. Br J Psychiatry 1999;175:12-6.
44. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The fourth generation of progress. New York: Raven Press; 1995. p. 1081.
45. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58(suppl 13):23-9.
46. Bridges PK. ...and a small dose of an antidepressant might help. Br J Psychiatry 1983;142:626-8.
47. Brugha TS, Bebbington PE, MacCarthy B, et al. Antidepressants may not assist recovery in practice: a naturalistic prospective study. Acta Psychiatr Scand 1992;86:5-11.
48. Fauman MA. Tricyclic antidepressant prescription by general hospital physicians. Am J Psychiatry 1980;237:490-1.
49. Johnson DAW. A study of the use of antidepressant medication in general practice. Br J Psychiatry 1974;125:186-92.
50. Keller MB, Klerman GL, Lavori PW, et al. Treatment received by depressed patients. JAMA 1982;248:1848-55.
51. Ketai R. Family practitioners knowledge about treatment of depressive illness. JAMA 1976;235:2600-3.
52. Kotin J, Post RM, Goodwin FK. Drug treatment of depressed patients referred for hospitalization. Am J Psychiatry 1973;130:1139-41.
53. Schatzberg AF, Cole JO, Cohen BM, et al. Survey of depressed patients who failed to respond to treatment. In: Davis JM, Maas JW, editors. The affective disorders. Washington, DC: American Psychiatric Press; 1983. p. 73.
54. Remick RA, Barton JS, Patterson B. On so-called treatment-resistant depression. Presented at 51st Annual Meeting of the Royal Collage of Physicians and Surgeons of Canada. Québec City, Québec, Canada, September 1982.
55. Nierenberg AA, Price LH, Charney DS, Heninger GR. After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression. J Affect Disord 1990;18:167-75.
56. Ravaris CL, Nies A, Robinson D, et al. A multiple dose controlled study of phenelzine in depression-anxiety states. Arch Gen Psychiatry 1976;33:347-50.
57. Simpson GM, Lee JH, Cuculica A, Kellner R. Two dosages of imipramine in hospitalized endogenous and neurotic depressives. Arch Gen Psychiatry 1976;33:1093-102.
58. Tyrer P, Gardner M, Lambourn J, Whitford M. Clinical and pharmacokinetic factors affecting response to phenelzine. Br J Psychiatry 1980;136:359-65.
59. Watt DC, Crammer JL, Elkes A. Metabolism, anticholinergic effects and therapeutic effects on outcome of desmethylimipramine in depressive illness. Psychol Med 1972;2:397-405.
60. Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989;25:71-9.
61. Preskorn SH, Lane RM. Sertraline 50 mg daily; the optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995;10:129-41.
62. Schweitzer E, Rickels K, Amsterdam JD, et al. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 1990;51:8-11.
63. Fava M, Rosenbaum JF, Cohen L, et al. High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J Affect Disord 1992;25:229-34.
64. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-4.
65. Kelsey JE. Dose-response relationship with venlafaxine. J Clin Psychopharmacol 1996;16(suppl 2):21S-8S.
66. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 18):4-11.
67. Ontiveros A, Fontaine R, Elie R. Refractory depression: the addition of lithium to fluoxetine or desipramine. Acta Psychiatr Scand 1991;83:188-92.
68. Baumann P, Souche A, Montaldi S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996;16:307-14.
69. Cournoyer G, de Montigny C, Oulette J, et al. Lithium addition in tricyclic-resistant unipolar depression: a placebo-controlled study. Presented at the XIVth Congress of the Collegium Internationale Neuropsychopharmacologicum (CINP). Florence, Italy, June 19-23, 1984.
70. de Montigny C, Cournoyer G, Morissette R, et al. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. Arch Gen Psychiatry 1983;40:1327-34.
71. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant action: an effective prescription for treatment refractory depression. Arch Gen Psychiatry 1983;40:1335-42.
72. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54:269-71.
73. Kantor D, McNeven S, Leichner P, et al. The benefit of lithium carbonate adjunct in refractory depression: fact or fiction? Can J Psychiatry 1986;31:416-8.
74. Katona CL, Abou-Saleh M, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995;166:80-6.
75. Schopf J, Baumann P, Lemarchand T, Rey M. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Pharmacopsychiatry 1989;22:183-7.
76. Stein G, Bernadt M. Double-blind trial of lithium carbonate in tricyclic resistant depression. In: Birch NJ, editor. Lithium: inorganic pharmacology and psychiatric use. Oxford: IRL Press; 1988. p. 35.
77. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiatry 1993;162:634-640.
78. Zusky PM, Biederman J, Rosenbaum JF, et al. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin Psychopharmacol 1988;8:120-4.
79. Prange Jr AJ. Novel uses of thyroid hormone in patients with affective disorders. Thyroid 1996;6:537-43.
80. Aronson R, Offman HJ, Joffe T, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996;53:842-8.
81. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective reuptake inhibitors in severe treatment-refractory depression. South Afr Med J 1997;87(suppl 4):534-7.
82. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 1998;18:465-9.
83. Jacobsen FM. A possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-20.
84. Landen M, Bjorling G, Agren H, Fahlen T. A randomized, double-blind, placebocontrolled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998;59:664-8.
85. Appelberg BG, Syvalahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001;62:448-52.
86. Fredman SJ, Fava M, Kienke AS, et al. Partial response, non-response, and relapse on SSRIs in major depression: a survey of current "next-step" practices. J Clin Psychiatry 2000;61:403-7.
87. Bodkin JA, Lasser RA, Wines Jr JD, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-45.
88. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol 1996;16:80-1.
89. Marshall RD, Randall D, Johannet CM, et al. Bupropion and sertraline combination treatment in refractory depression. J Psychopharmacol 1995;9:284-6.
90. Spier SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety 1998;7:73-5.
91. Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999;60:45-9.
92. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of mirtazapine augmentation for refractory depression. Biol Psychiatry 2002;51:183-8.
93. Debonnel G, Gobbi G, Turcotte J, et al. The α2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double-blind controlled study. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 10-14, 2000.
94. Fava GA, Rafanelli C, Grandi S, et al. Prevention of recurrent depression with cognitive therapy: preliminary findings. Arch Gen Psychiatry 1998;55:816-20.
95. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998;59(suppl 14):11-4.
96. van Praag H, Asnis GM, Kahn RS, et al. Monoamines and abnormal behaviour: a multiaminergic perspective. Br J Psychiatry 1990;157:723-34.
97. Fulgum E, Rosenberg C, Damsbo N, et al. Screening and treating depressed patients: a comparison of two controlled citalopram trials across treatment settings: hospitalized patients versus patients treated by their family doctors. Acta Psychiatr Scand 1996;94:18-25.
98. McGrath PJ, Stewart JW, Nunes EN, Quitkin FM. Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant. J Clin Psychiatry 1994;55:336-9.
99. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993;150:118-23.
100. Thase ME, Mallinger AG, McKnight D, Himmelhoch HM. Treatment of imipramineresistant recurrent depression,. IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992;149:195-8.
101. Beasley Jr CM, Sayler ME, Cunningham GE, et al. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 1990;20:193-200.
102. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 2000;61(suppl 2):10-2.
103. Joffe RT, Levitt AJ, Sokolov ST, Young LT. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-5.
104. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58:16-21.
105. Thase ME, Lydiard RB, Feighner JP. Citalopram treatment of fluoxetine nonresponders. J Clin Psychiatry 2001;62:683-7.
106. Guy W. ECDEU assessment manual for psychopharmacology revised, 1976. Rochville MD: U.S. Department of Health, Education and Welfare. DHEW Publication No. (ADM) 76-338; 1976. p. 218.
107. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002;59:233-9.
108. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-23.
109. de Montigny C, Silverstone PH, Debonnel G, et al. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999;19:401-6.
110. Fava M, Dunner DL, Greist JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 2001;62:413-20.
111. Rush AJ, Crismon ML, Toprac MG, et al. Implementing guidelines and systems of care: experiences with the Texas Medication Algorithm Project (TMAP). J Pract Psychiatry Behav Health 1999;5:75-86.
112. Rush AJ. Linking efficacy and effectiveness research in the evaluation of psychotherapies. In: Miller NE, McGruder KM, editors. Cost-effectiveness of psychotherapy: a guide for practitioners, researchers, and policy makers. New York: Oxford University Press; 1999. p. 26.
113. Kobak KA, Griest JH, Jefferson JW, et al. Computerized assessment of depression and anxiety over the telephone using Interactive Voice Response. MD Comput 1999;16:61-8.
114. Basco MR, Rush AJ. Compliance with pharmacotherapy in mood disorders. Psychiatr Ann 1995;25:269-79.
115. Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 1999;56:829-35.
116. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988;45:742-7.
117. Rush AJ, Giles DE, Schlesser MA, et al. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 1986;18:65-87.
118. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996;26:477-86.
119. Ware JE Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33.
120. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65.
121. Mundt JC, Kobak KA, Greist JH, Marks IM. Work and social adjustment scale: an alternative quality-of-life instrument. Presented at the 39th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU). Boca Raton, FL, June 1-4, 1999.
122. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
123. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q): a new measure. Psychopharmacol Bull 1993;29:321-6.
124. Clark RE, Ricketts SK, McHugo GJ. Measuring hospital use without claims: a comparison of patient and provider reports. Health Serv Res 1996;31:153-69.
125. Dresser MVB, Feingold L, Rosenkranz SL, Coltin KL. Clinical quality measurement: comparing chart review and automated methodologies. Med Care 1997;35:539-52.
126. Kashner TM. Agreement between administrative files and written medical records: a case of the Department of Veterans Affairs. Med Care 1998;36:1324-36.
127. Kashner TM, Rost K, Smith GR, Lewis S. An analysis of panel data: the impact of a psychiatric consultation letter on the expenditures and outcomes of care for patients with somatization disorder. Med Care 1992;30:811-21.
128. Magaziner J, Simonsick EM, Kashner TM, Hebel JR. Patient-proxy response comparability on measures of patient health and functional status. J Clin Epidemiol 1988;41:1065-74.
129. Quam L, Ellis LBM, Venus P, et al. Using claims data for epidemiologic research: the concordance of claim-based criteria with the medical record and patient survey for identifying a hypertensive population. Med Care 1993;31:498-507.
130. Kashner TM, Rush AJ, Altshuler KZ. Measuring costs of guideline-drive mental health care: The Texas Medication Algorithm Project. J Ment Health Policy Econ 1999;2:111-121.
131. Rush AJ, Rago WV, Crismon ML, et al. Medication treatment of the severely and persistently mentally ill: The Texas Medication Algorithm Project. J Clin Psychiatry 1999;60:142-56.
132. Keller MB. Pharmacotherapy and psychotherapy: New data on the long-term treatment of chronic depression. Presented at the 154th Annual Meeting of the American Psychiatric Association. New Orleans LA, May 5-10, 2001.
133. Lavori PW, Rush AJ, Wisniewski SR, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry 2001;50:792-801.
134. Cooper-Patrick L, Powe NR, Jenckes MV, et al. Identification of patient attitudes and preferences regarding treatment of depression. J Gen Intern Med 1997;12:431-8.
135. Eisenthal S, Emery R, Lazare A, Udin H. "Adherence" and the negotiated approach to patienthood. Arch Gen Psychiatry 1979;36:393-8.
136. Frank E, Kupfer DJ, Siegel LR. Alliance not compliance: a philosophy of outpatient care. J Clin Psychiatry 1995;56(suppl 1):11-7.
137. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry 1989;46:971-82.
138. Ezra KR. An analysis of treatment preferences in patients of a late life depression clinic. Dissertation Abstracts International: Section B: The Sciences and Engineering 1997;57(8-B):5324.
139. Nierenberg AA, Mulroy R. Declaration of treatment failures. In: Rush AJ, editor. Modern problems of pharmacopsychiatry, vol. 25. Mood disorders. Systematic medication management. Basel, Switzerland: S. Karger; 1997. p. 17.
140. Rush AJ, Kupfer DJ. Strategies and tactics in the treatment of depression. In: Gabbard GO, editor. Treatments of psychiatric disorders, vol. 2. 3rd edition. Washington, DC: American Psychiatric Press; 2001: p. 1417.
141. Meterissian GB, Bradwejn J. Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: was adequate pharmacotherapy provided? J Clin Psychopharmacol 1989;9:334-9.
142. Quitkin FM, Rabkin JG, Ross D, McGrath PJ. Duration of antidepressant drug treatment, what is an adequate trial? Arch Gen Psychiatry 1984;41:238-45.
143. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytic approach. Eur Neuropsychopharmacol 1993;3:127-35.
144. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333-40.
145. Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance. A systematic review of the effect of continuing medical education strategies. JAMA 1995;274:700-5.
146. Evans CE, Haynes RB, Birkett NJ, et al. Does a mailed continuing education program improve physician performance? JAMA 1986;255:501-4.
147. Headrick LA, Speroff T, Pelecanos HI, Cebul RD. Efforts to improve compliance with the national Cholesterol Education Program guidelines. Arch Intern Med 1992;152:2490-6.
148. Margolis CZ, Warshawsky SS, Goldman L, et al. Computerized algorithms and pediatricians' management of common problems in a community clinic. Acad Med 1992;67:282-4.
149. Tierney WM, Hui SL, McDonald CJ. Delayed feedback of physician performance versus immediate reminders to perform preventive care: effects on physician compliance. Med Care 1986;24:659-66.
150. Anderson FA, Wheeler HB, Goldberg FJ, et al. Changing clinical practice: prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism. Arch Intern Med 1994;154:669-77.
151. Gemson DH, Ashford AR, Dickey LL, et al. Putting prevention into practice: impact of a multifaceted physician education program on preventive services in the inner city. Arch Fam Med 1995;155:2210-6.
152. Hunt DL, Haynes RB, Hanna SE, Smith K. Effects of computer-based clinical decision support systems on physician performance and patient outcomes. JAMA 1998;280:1339-46.
153. Francis A, Docherty JR, Kahn DA. The Expert Consensus Guideline Series: treatment of schizophrenia. J Clin Psychiatry 1996;57(suppl 12A):1-58.
154. Francis A, Docherty JR, Kahn DA. The Expert Consensus Guideline Series: treatment of bipolar disorder. J Clin Psychiatry 1996;57(suppl 12B):1-88.
155. Schoenbaum SC, Gottlieb LK. Algorithm based improvement of clinical quality. BMJ 1990;301:1374-6.
156. Guiterrez G, Guiscarfe H, Bronfman M, et al. Changing physician prescribing patterns: evaluation of an educational strategy for acute diarrhea in Mexico City. Med Care 1994;32:436-46.
157. Hristov DH, Fallone BG. An active set algorithm for treatment planning optimization. Med Phys 1997;24:1455-64.
158. Roland PY, Naumann RW, Alvarez RD, et al. A decision analysis of practice patterns used in evaluating and treating abnormal pap smears. Gynecol Oncol 1995;59:75-80.
159. Brennan PJ, Abrutyn E. Developing policies and guidelines. Infect Control Hosp Epidemiol 1995;16:512-7.